Inebilizumab in autoimmune hepatitis

Phase 3, randomised, double-blind trial of inebilizumab in autoimmune hepatitis (AIH) (4 arms), sponsored by Amgen. Primary endpoints: Number of participants who experienced treatment-emergent adverse events, serious treatment-emergent adverse events, and treatment-emergent adverse events of interest at Week 26 and Number of participants who achieved modified Histologic Activity Index less than or equal to 3 and stable prednisone dose or equivalent less than or equal to 5 mg/day at Week 78. Started Oct 2026; status: recruiting.